IRCT20200105046010N79 IRCT 2023-07-11 Tabriz University of Medical Sciences Bioequivalence study of Tofacitinib 10 mg tablet Bioequivalence study of Tofacitinib 10 mg tablet manufactured by Cobel daru versus originator brand in healthy volunteers in the fasted condition 2023-06-22 anticipated 24 Complete https://irct.ir/trial/70691 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball, poured into a container, and mixed. The balls are then removed randomly from the container and divided into 2 groups of 12 test (A) and reference (B) drug recipients, then in the second phase, groups A and B will be cross-referenced to the test and drug recipients, Blinding description: This study is a single-blinded clinical trial (volunteers). Cobel daru's Tofacitinib and Originator brand capsules are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form. Bioequivalence This study is performed on healthy volunteers.. Intervention 1: Intervention group 1: single dose, one oral tablet 10 mg (Xeljanz) manufactured by Pfizer company, as a reference product. Intervention 2: Intervention group 2: Single dose, one oral Alpamon 10 mg tablet manufactured by Cobel daru company as a test product. The washout period is one week. in the second sequence of sampling, the volunteers that consumed the test drug will consume the reference drug and vice versa. No - There is not a plan to make this available Justification or reason for not sharing IPD is These data are as secure between researchers and related industries.